$Recro Pharma(REPH)$ 内部交易: 2017-05-03,10% Owner,Stonepine Capital Management, ,卖出,16148普通股, $7.79
$Recro Pharma(REPH)$ 8-K - Current report Filed: 2017-04-05 AccNo: 0001193125-17-110946 Size: 15 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Recro Pharma(REPH)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-03-28 AccNo: 0001193125-17-099846 Size: 540 KB 网页链接
$Recro Pharma(REPH)$ DEF 14A - Other definitive proxy statements Filed: 2017-03-28 AccNo: 0001193125-17-099836 Size: 956 KB 网页链接
$Recro Pharma(REPH)$ 内部交易: 2017-03-16,10% Owner,SCP Vitalife Partners II LP ,卖出,9488普通股, $7.93
$Recro Pharma(REPH)$ 内部交易: 2017-03-15,10% Owner,SCP Vitalife Partners II LP ,卖出,19161普通股, $8.01
$Recro Pharma(REPH)$ 内部交易: 2017-03-14,10% Owner,SCP Vitalife Partners II LP ,卖出,16328普通股, $8.04
$Recro Pharma(REPH)$ 内部交易: 2017-03-16,10% Owner,SCP Vitalife Partners (Israel) ,卖出,3170普通股, $7.93
$Recro Pharma(REPH)$ 内部交易: 2017-03-15,10% Owner,SCP Vitalife Partners (Israel) ,卖出,6399普通股, $8.01
$Recro Pharma(REPH)$ 内部交易: 2017-03-14,10% Owner,SCP Vitalife Partners (Israel) ,卖出,5454普通股, $8.04